Related Experiment Video
Updated: Jun 27, 2026

Purification and Refolding to Amyloid Fibrils of (His)6-tagged Recombinant Shadoo Protein Expressed as Inclusion Bodies in E. coli
Published on: December 19, 2015
Spontaneous beta-helical fold in prion protein: the case of PrP(82-146)
Gloria A A Saracino1, Alessandra Villa, Giorgio Moro
1Dipartimento di Biotecnologie e Bioscienze, University of Milano-Bicocca, piazza della Scienza 2, 20126 Milano, Italy.
Abstract:
The presence of amyloid is a hallmark of Gerstmann-Sträussler-Scheinker (GSS) disease, which is a prion disease caused by germ line mutations in the PRNP gene. The major component of amyloid is a fragment spanning residues from 81-82 to 144-153, part of the minimal sequence thought to play a crucial role in the conversion reaction and to sustain prion replication. We present here a molecular dynamics study on the 82-146 peptide from the human prion protein. The aim is to identify its aggregation-prone folds. The 82-146 prion sequence corresponds to a naturally occurring prion peptide able to form fibrils rich in parallel beta-sheets. A spontaneous right-handed beta-helical arrangement with 13 residues per turn can be observed in the 103-135 segment of the 82-146 peptide. The observed fold is in accordance with the evidence of a parallel beta-sheet organization in amyloid and with experiments on 82-146 discussed in the literature. To elucidate the conformational properties that trigger this peptide's aggregation propensity, the conformational behavior of peptides of different length (106-126 and 113-120 prion segments) was also investigated. Simulation analysis has led to some interesting considerations on sequence specific flexibility and the effects of growth. Comparing peptides of different length allows the localization of the origin of the beta-helix conformational propensity in the 106-126 segment, though longer sequences appear necessary for a clear beta-helical arrangement. Structural features of the observed 82-146 beta-helical fold are compatible with the "dock and lock" mechanism proposed to interpret peptide aggregation kinetics.
Insights
This study reveals that the 82-146 peptide from the human prion protein spontaneously forms a beta-helical structure, crucial for amyloid formation in Gerstmann-Sträussler-Scheinker disease. This finding aids understanding of prion disease mechanisms.
Area of Science:
- Biophysics
- Neuroscience
- Molecular Biology
Background:
- Amyloid formation is a key feature of Gerstmann-Sträussler-Scheinker (GSS) disease, a prion disease.
- The human prion protein (PRNP) gene mutations cause GSS disease.
- A specific fragment (residues 81-82 to 144-153) of the prion protein is central to amyloid formation and prion replication.
Purpose of the Study:
- To investigate the aggregation-prone folds of the 82-146 peptide from the human prion protein using molecular dynamics.
- To understand the conformational properties driving the aggregation propensity of this prion peptide.
Main Methods:
- Molecular dynamics simulations were performed on the 82-146 peptide of the human prion protein.
- Conformational behavior of shorter prion segments (106-126 and 113-120) was also analyzed to pinpoint aggregation origins.
Main Results:
- A spontaneous right-handed beta-helical arrangement was observed in the 103-135 segment of the 82-146 peptide.
- This beta-helical fold is consistent with parallel beta-sheet organization in amyloid fibrils.
- The 106-126 segment was identified as the origin of beta-helix conformational propensity, with longer sequences favoring a distinct arrangement.
Conclusions:
- The identified beta-helical fold of the 82-146 peptide is compatible with the 'dock and lock' model of peptide aggregation kinetics.
- Findings provide insights into the structural basis of prion peptide aggregation and GSS disease pathogenesis.
Related Concept Videos
Protein Folding
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
Protein Folding
Protein Folding
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Molecular Chaperones and Protein Folding
The...

